Table 4.

Univariate and multivariate analysis (first model)

			PFS							OS

			Univ			Multiv				Univ			Multiv

Factor		N	HR	95% CI	p-value	HR	95% CI	p-value	% selection	HR	95% CI	p-value	HR	95% CI	p-value	% selection
p53	wt	825	1		0.0005	–		–	26.4	1		<0.0001	1		0.036	62.0
	mut	644	1.37	1.16–1.62						1.80	1.43–2.27		1.32	1.02–1.73
	missing	387	1.04	0.84–1.28						1.10	0.81–1.50		0.93	0.67–1.30

Stage	LO	1429	1		<0.0001	–		–	14.1	1		<0.0001	–		–	7.9
Stage	LABC/T4d	421	2.18	1.86–2.55						2.48	2.00–3.07

cT	T1–2	930	1		<0.0001	1		<0.0001	100	1		<0.0001	1		<0.0001	99.9
	T3	573	1.89	1.58–2.27		1.97	1.63–2.39			1.96	1.51–2.55		1.97	1.49–2.60
	T4	352	3.03	2.50–3.66		2.78	2.25–3.43			3.42	2.63–4.44		2.99	2.24–4.00

cN	N0	792	1		<0.0001	1		<0.0001	100	1		<0.0001	1		<0.0001	100
	N1	924	1.73	1.46–2,04		1.46	1.22–1.75			2.23	1.74–2.87		1.88	1.43–2.47
	N2	116	2.44	1.84–3.25		1.67	1.22–2.28			3.55	2.44–5.17		2.34	1.55–3.53
	N3	20	7.43	4.46–12.39		5.47	3.19–9.38			11.72	6.23–22.04		6.49	3.29–12.79

PS	0	1748	1		<0.0001	1		0.0008	90.7	1		0.0008	1		0.007	71.6
PS	1 (2 pts with 2)	108	1.80	1.38–2.35		1.65	1.23–2.21			1.81	1.27–2.56		1.68	1.15–2.46

Age	50 or more	766	1		0.33	–		–	23.3	1		0.12	–		–	7.7
Age	<50	1090	0.93	0.80–1.08						0.85	0.69–1.05

Menopausal status	Post	752	1		0.14				10.7	1		0.08				8.7
Menopausal status	Pre	1099	0.89	0.77–1.04						0.83	0.67–1.03

Endocrine receptors	ER+ and/or PgR+	1154	1		<0.0001	–	–	–	13.7	1		<0.0001				16.3
Endocrine receptors	ER− and PgR−	506	1.94	1.65–2.28						2.39	1.92–2.98

Histological type	Lobular	200	1		0.089				11.2	1		0.16
	Ductal	1546	1.27	0.98–1.65						1.38	0.94–2.02
	Other	94	1.52	1.03–2.27						1.65	0.95–2.87

Grade	1	121	1		<0.0001	1		0.018	78.2	1		<0.0001	–		–	28.7
	2	859	2.10	1.36–3.24		1.55	0.99–2.43			2.65	1.30–5.40
	3	615	3.15	2.04–4.87		1.74	1.10–2.75			4.34	2.13–8.84
	Not assessed	253	2.31	1.45–3.68		1.22	0.74–2.01			3.32	1.58–6.99

Treatment arm (stratified, 98.3% CI)	FEC	928	1		0.035	–		–	44.7	1		0.28	–		–	29.9
Treatment arm (stratified, 98.3% CI)	T-ET	928	0.85	0.71–1.02						0.89	0.69–1.14

Endoc Ttt	Tam/AI	1290	1		<0.0001	1		<0.0001	98.6	1		<0.0001	1		<0.0001	93.0
Endoc Ttt	None	566	2.11	1.81–2.46		1.95	1.62–2.33			2.59	2.10–3.19		2.27	1.78–2.89

Abbreviations: cT: clinical tumour size; cN: clinical nodal status; PS: performance status; Endoc Ttt: endocrine treatment; wt: wild type; mut: mutated; LO: large operable; LABC: locally advanced breast cancer; ER: estrogen receptor; PgR: progesterone receptor; FEC: 5-fluorouracil, epirubicin, and cyclophosphamide; T-ET: docetaxel followed by epirubicin and docetaxel; Tam: tamoxifen; AI: aromatase inhibitor; PFS: progression-free survival; OS: overall survival; Univ: univariate; Multiv: multivariate; HR: hazard ratio; CI: confidence interval; % selection: % of times the covariate remained (by backward selection) in the final model in bootstrapped (resampled) models.